The FDA has approved a new therapy for the treatment of acute uncomplicated influenza in patients 18 years and older. RAPIVAB is a single-dose intravenous neuraminidase inhibitor, and the first new antiviral treatment approved for the flu within the last 15 years. Clinical trials involving over 2,700 patients showed that the drug improved flu symptoms and reduced fever much more than placebo.
Read the press release here
